Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.38 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | TACR1 | P25103 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1751111 | 0.76 | L3MBTL1 (0.57) | L3MBTL1KDM4EMEN1KMT2AMAPT | |
| SCHEMBL1751887 | 0.72 | L3MBTL1 (0.43) | L3MBTL1KDM4EMEN1KMT2ATSHR | |
| SCHEMBL12021126 | 0.71 | L3MBTL1 (0.39) | L3MBTL1KDM4EMEN1KMT2ATSHR | |
| SCHEMBL12529495 | 0.67 | NISCH (0.36) | L3MBTL1KDM4EMEN1KMT2ATSHR | |
| SCHEMBL1751586 | 0.67 | NISCH (0.36) | L3MBTL1KDM4EMEN1KMT2ATSHR | |
| SCHEMBL1751888 | 0.67 | L3MBTL1 (0.36) | L3MBTL1KDM4EMEN1KMT2ATSHR | |
| SCHEMBL7246918 | 0.66 | CARM1 (0.40) | — | |
| SCHEMBL27721820 | 0.66 | L3MBTL1 (0.56) | L3MBTL1KDM4EMEN1KMT2ATSHR | |
| SCHEMBL2557802 | 0.63 | L3MBTL1 (0.56) | L3MBTL1KDM4EMEN1KMT2ATSHR | |
| SCHEMBL1751084 | 0.62 | HRH3 (0.40) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9840464-B2 | IAP binding compounds | TetraLogic Birinapant UK Ltd. (GB) | 2017-12-12 | — | — | US | disclosed |
| US-20160289183-A1 | IAP Binding Compounds | TETRALOGIC PHARMACEUTICALS CORPORATION | 2016-10-06 | — | — | US | disclosed |
| US-9394249-B2 | IAP binding compounds | TetraLogic Birinapant UK Ltd. (GB) | 2016-07-19 | — | — | US | disclosed |
| US-20150307448-A1 | IAP Binding Compounds | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2015-10-29 | — | — | US | disclosed |
| US-8802716-B2 | IAP binding compounds | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2014-08-12 | — | — | US | disclosed |
| US-20130289075-A1 | IAP BINDING COMPOUNDS | TETRALOGIC PHARMACEUTICALS CORPORATION | 2013-10-31 | — | — | US | disclosed |
| US-20110294827-A1 | IAP BINDING COMPOUNDS | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2011-12-01 | — | — | US | disclosed |
| US-7968590-B2 | IAP binding compounds | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2011-06-28 | — | — | US | disclosed |
| US-20090048183-A1 | IAP BINDING COMPOUNDS | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2009-02-19 | — | — | US | disclosed |
| US-7456209-B2 | IAP binding compounds | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2008-11-25 | — | — | US | disclosed |
| US-20060025347-A1 | IAP binding compounds | MEDIVIR AB (SE) | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160289183-A1 | IAP Binding Compounds | BIRC5, API5, BIRC2 | L3MBTL1 434/4885KDM4E 3837/4885MEN1 2970/4885 |
| US-20130289075-A1 | IAP BINDING COMPOUNDS | API5, BIRC5, BIRC2 | L3MBTL1 420/4885KDM4E 3767/4885MEN1 3007/4885 |
| US-20150307448-A1 | IAP Binding Compounds | BIRC5, API5, BIRC2 | L3MBTL1 434/4885KDM4E 3837/4885MEN1 2970/4885 |
| US-20110294827-A1 | IAP BINDING COMPOUNDS | BIRC5, BIRC2, API5 | L3MBTL1 389/4885KDM4E 3718/4885MEN1 2999/4885 |
| US-20060025347-A1 | IAP binding compounds | BIRC5, BIRC2, API5 | L3MBTL1 389/4885KDM4E 3718/4885MEN1 2999/4885 |
| US-20090048183-A1 | IAP BINDING COMPOUNDS | BIRC5, BIRC2, API5 | L3MBTL1 389/4885KDM4E 3718/4885MEN1 2999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.